Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Kailera and partner Hengrui Pharma presented positive clinical data for ribupatide at the ADA 2026 conference, highlighting the asset's potential as a differentiated obesity treatment. Phase 2 data for the oral formulation showed a mean weight loss of 12.1% at 25 mg and 50 mg doses, with 38.6% of participants on the 25 mg dose achieving at least 15% weight loss at 26 weeks. Phase 1 bridging data for the injection formulation demonstrated similar exposure and tolerability in non-Asian participants compared to Asian cohorts, supporting the ongoing global Phase 3 KaiNETIC program.
Key figures
- Drug Name
- ribupatide
- Phase Of Trial
- Phase 2 (oral), Phase 1 (injection)
- Oral trial participants
- 166
- Oral mean weight loss 25mg
- 12.1%
- Oral mean weight loss 50mg
- 12.1%
- Injection trial participants
- 49
- Injection mean weight loss 1mg
- 1.4%
- Injection mean weight loss 3mg
- 5.5%
- Oral participants ge 10pct loss 25mg
- 59.1%
- Oral participants ge 10pct loss 50mg
- 52.5%
- Oral participants ge 15pct loss 25mg
- 38.6%
- Oral participants ge 15pct loss 50mg
- 37.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.